Orally disintegrating tablet containing brexpiprazole and preparation method thereof
By using sodium carboxymethyl starch as a binder, mannitol and microcrystalline cellulose as fillers in the preparation of brapiprazole oral collapse tablets, the problems of particle uniformity and disintegration speed are solved, and rapid disintegration is achieved , Brapiprazole oral collapse tablets with fast dissolution and good stability, suitable for large-scale industrial production.
Patent Information
- Application Number
- CN202411056593.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-02
- Publication Date
- 2024-11-22
AI Technical Summary
The existing preparation method for brapiprazole oral collapse sheets has problems with poor particle uniformity, slow disintegration, poor compressibility, and sticking. The micronized raw materials are prone to static electricity, which increases the risk of insufficient production costs and bioavailability.
Sodium carboxymethyl starch is used as the binder for fluidized bed granulation, combining mannitol and microcrystalline cellulose as filler to control the average particle size and auxiliary material ratio of microcrystalline cellulose, which solves the problem that there are many fine particles. The disintegration time limit exceeds the problem of poor compressibility, and the preparation of oral collapse sheets with fast disintegration, rapid dissolution and good stability is achieved.
The rapid disintegration, rapid dissolution, low cost and good stability of the brapiprazole oral collapse sheets are achieved during the preparation process. They are suitable for large-scale industrial production, significantly improving bioavailability and reducing production costs.
Smart Images

Figure CN118986904A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to an orally disintegrating tablet containing brepazole and a preparation method thereof. Background Art
[0002] Brepirapazole, also known as epiriprazole, is a once-daily second-generation (atypical) oral antipsychotic drug discovered by Otsuka and jointly developed by Lundbeck and Otsuka. Brepirapazole tablets were approved by the FDA in July 2015 under the trade name Rexulti for the treatment of major depressive disorder (MDD) and schizophrenia, and were approved in 2016 for the maintenance treatment of adult patients with schizophrenia. At the end of July 2018, Brepirapazole tablets were approved for marketing in Europe by the European Union for the treatment of adult patients with schizophrenia. Mechanism of action and clinical application: Brepirapazole has a regulatory effect on the monoaminergic neurotransmission system in the brain. It is a partial agonist of serotonin receptor 5-HT1A and dopamine receptors D2 and D3. It is also a partial antagonist of serotonin receptors 5-HT2A and 5-HT2B and adrenaline receptors α-1 and α-2.
[0003] In November 2021, Otsuka Pharmaceutical's breprazol orally disintegrating (OD) tablets were approved by Japanese regulators for marketing under the trade name Rexulti OD tablets. Rexulti OD tablets are a dosage form that disintegrates rapidly in the mouth. The launch of orally disintegrating tablets provides a convenient option for patients who cannot take tablets due to difficulty swallowing.
[0004] Brepirapazole, chemical name 7-[4-(4-benzo[B]thiophen-4-yl-1-piperazine)butoxy]-2(1H)-quinolinone; the properties are off-white or off-white crystalline powder, and the chemical structure is:
[0005]
[0006] Patent CN106580902A discloses an orally disintegrating tablet of epiprazole and a preparation method thereof. In the preparation process, the orally disintegrating tablet is prepared by ordinary wet granulation, oven drying, total mixing and tableting. Because the steps are complicated and the uniformity of the prepared particles is poor, it is difficult to achieve the effect of rapid disintegration, and the mouthfeel is prone to gritty feeling, and the patient compliance is poor. In addition, the problem of incomplete dissolution endpoint caused by the change of properties of the raw materials after micronization, which is easy to generate static electricity and easy to agglomerate, is not paid attention to, and a medium with discriminating power is not found to evaluate the dissolution behavior, which will significantly increase the risk of insufficient drug bioavailability.
[0007] Patent CN115998694A discloses a brepazine orally disintegrating tablet and a preparation method thereof, wherein the preparation method is a powder direct compression process. Although the process is simple, the raw materials based on small-sized drugs and after micronization are prone to static electricity, and the raw material particle size control is small, and the content and mixing uniformity are difficult to control, which increases the complexity of the subsequent mixing method and the compressibility of the total mixed powder. In addition, the powder direct compression process has high requirements on the properties of raw materials and auxiliary materials, which will undoubtedly increase the production cost.
[0008] Patent CN105078910A discloses a freeze-dried oral preparation containing brepazole and a preparation method thereof. The freeze-dried oral preparation is prepared from raw materials and auxiliary materials by freeze-drying, which can disintegrate quickly, so that brepazole can be quickly dissolved and absorbed by patients, thereby improving bioavailability. However, the preparation method is relatively cumbersome, and has high requirements for equipment and personnel. The freeze-dried product is easy to break during transportation, and the moisture content needs to be strictly controlled during storage. The storage conditions are high, which is not conducive to the use of patients with mental illness.
[0009] Patent CN116763746A discloses a brepirazole orally disintegrating tablet and a preparation method thereof, which solves the problems of poor dissolution and slow disintegration rate by top-spraying granulation of brepirazole, a complexing agent (solubilizer) and a 50% ethanol-water solution in a fluidized bed. However, although the preparation method can improve the dissolution rate, its shortcomings are also obvious: first, a large amount of solubilizer is used in the formula, which poses a great risk to patient safety; second, the use of a 50% ethanol-water solution for granulation requires high equipment safety, and ethanol is easy to be released, resulting in difficulty in process control, and the compressibility of the tablets and the disintegration time limit of the orally disintegrating tablets are not investigated. Summary of the invention
[0010] The purpose of the present invention is to provide an orally disintegrating tablet containing brepazine on the basis of the prior art, which overcomes the adverse effects caused by the small size of the active raw material and the surface properties after micronization, and solves the problem that the common wet granulation granules have more fine powders, which brings challenges to the tableting process (for example, cracking, sticking, and poor compressibility) or the disintegration time limit of large particles is exceeded. Sodium carboxymethyl starch is used as a binder for fluidized bed one-step granulation, and the particle size of the filler microcrystalline cellulose is controlled at the same time, which solves the problems of slow disintegration, sticking, and poor compressibility of the orally disintegrating tablet in the preparation process. The present invention has the advantages of simple preparation method, high safety, low cost, good product content uniformity, rapid dissolution, good compressibility, smooth and non-sticky tablet surface, good stability, etc., and is suitable for large-scale industrial production.
[0011] Another object of the present invention is to provide a method for preparing the orally disintegrating tablet containing brepazole.
[0012] The technical solution of the present invention is as follows:
[0013] An orally disintegrating tablet containing brepazole is prepared from the following components in parts by weight: 0.5-5 parts of active ingredient brepazole, 5-25 parts of microcrystalline cellulose, 60-80 parts of mannitol, 0.5-2 parts of sodium carboxymethyl starch, 6-18 parts of low-substituted hydroxypropyl cellulose, 0.5-2 parts of sodium stearyl fumarate and 0.05-0.15 parts of a sweetener.
[0014] In a preferred embodiment, during the preparation of the orally disintegrating tablet, the active ingredients of borax, microcrystalline cellulose and mannitol are firstly mixed evenly, and then fluidized bed granulated with a binder solution prepared by dispersing sodium carboxymethyl starch in purified water, and the obtained wet granules are dried and granulated; and then mixed with sodium stearyl fumarate and a sweetener for tableting.
[0015] The orally disintegrating tablet containing breprazol provided by the present invention comprises an active ingredient breprazol and excipients. The excipients include fillers, disintegrants, binders, flavoring agents and lubricants. The fillers are mannitol and microcrystalline cellulose, wherein the average particle size of the microcrystalline cellulose is 10 to 80 μm; sodium carboxymethyl starch is used as a binder, the disintegrant is low-substituted hydroxypropyl cellulose; and the lubricant is sodium stearyl fumarate. The flavoring agent is an edible flavor or a sweetener, for example, it can be one or more of strawberry flavor, mint flavor, sucrose, sucralose or aspartame.
[0016] Because brepazole is an antipsychotic drug and has large toxic and side effects, the present invention uses sodium carboxymethyl starch as a binder to perform fluidized bed one-step granulation, which can reduce the safety problems caused by cross contamination and large dust. In addition, by screening auxiliary materials (sodium carboxymethyl starch as a binder) and controlling the ratio of each auxiliary material, the average particle size of the filler microcrystalline cellulose is controlled, and the problems of sticking and poor compressibility of the orally disintegrating tablet in the preparation process are effectively solved. The orally disintegrating tablet has the advantages of simple preparation method, high safety, low cost, good product content uniformity, rapid dissolution, good compressibility, smooth and non-sticky tablet surface, good stability, etc., and is suitable for large-scale industrial production.
[0017] The present invention aims to explore the problems of disintegration time limit, slow dissolution, poor compressibility and easy sticking during the preparation process of orally disintegrating tablets. A large number of existing auxiliary materials are screened through a large number of experiments, and the ratio and dosage of each auxiliary material are adjusted, in order to explore an orally disintegrating tablet that can maintain stability, disintegrate rapidly and dissolve quickly, and solve the problems of sticking, poor compressibility and slow disintegration of orally disintegrating tablets during tablet compression.
[0018] The invention adopts sodium carboxymethyl starch as a binder, mixes the binder solution with purified water to perform fluidized bed granulation, uses less amount, and prepares particles with uniform size, less fine powder, uniform content, and better subsequent tableting performance, without tablet cracking or sticking, with smooth and glossy tablet surface, and the tablet disintegrates quickly, meeting the requirement that the orodisintegrating tablet disintegration time limit is ≤1min.
[0019] Using sodium carboxymethyl starch as a binder can not only prepare granules and powders with uniform particle size and good fluidity, but also sodium carboxymethyl starch is a conventional disintegrant with good disintegration effect. The prepared granules can also have good disintegration effect when they are large, and have a synergistic effect on the disintegration time limit of granulation, tableting and orodisintegrating tablets. It successfully solves the problems of excessive cohesion during the use of ordinary binders, more fine particles and poor particle fluidity caused by less binder usage, and even when a lubricant is added, there are still problems of sticking, cracking and poor compressibility. Using sodium carboxymethyl starch as a binder has the characteristics of simple operation, smooth tableting and high efficiency in the entire preparation process, and the prepared tablets have the advantages of rapid disintegration, faster dissolution, low cost, good brittleness, smooth tablet surface and good stability.
[0020] For the present invention, the fillers are mannitol and microcrystalline cellulose. In a preferred embodiment, the average particle size of the microcrystalline cellulose is 15 to 65 μm. For example, the average particle size of the microcrystalline cellulose is 15 or 65 μm. When the average particle size of the microcrystalline cellulose is high, the mouthfeel of the orally disintegrating tablet obtained is poor, there is a sense of gravel, and it is not possible to achieve a good bitterness masking effect, and the disintegration time is slowed down. In addition, since the particle size of the raw material of brepazole is small and it is a micronized raw material, the microcrystalline cellulose can well eliminate the electrostatic adsorption of the fluidized bed during the granulation process. By controlling the average particle size of the microcrystalline cellulose, the mixing uniformity when granulated with the raw material can be well controlled. In addition, since the average particle size of the microcrystalline cellulose is small, the bitterness of the raw material can be better masked, making the taste more delicate and having better compliance with taking.
[0021] Sodium starch glycolate is usually used as a conventional super disintegrant and is widely used in tablets because sodium starch glycolate has a certain viscosity. In the present invention, sodium starch glycolate with a certain viscosity is selected as a binder for fluidized bed granulation, which solves the problem that the granules have good fluidity but slow disintegration when the amount of common binders is large, and solves the problem that the granules have more fluidity and poor compressibility when the amount of common binders is small. For the present invention, the filler is mannitol and microcrystalline cellulose, and the average particle size of microcrystalline cellulose is 15-65μm, which well solves the problems of low content, stickiness, poor compressibility, disintegration timeout and mouthfeel in the preparation process of small-sized orally disintegrating tablets.
[0022] For the present invention, the particle size D90 of the active ingredient boripiprazole after crushing is 10-50 μm, preferably 20-45 μm. Although the raw materials are micronized, the safety problems caused by large dust and the problem of mixing uniformity can be well controlled by one-step granulation in a fluidized bed. The preparation method is simple, safe and efficient.
[0023] In a preferred embodiment, the orally disintegrating tablet containing brepizole mentioned in the present invention is made of the following components in parts by weight: 2-3 parts of brepizole, 10-20 parts of microcrystalline cellulose, 65-75 parts of mannitol, 0.8-1.5 parts of sodium starch glycolate, 10-14 parts of low-substituted hydroxypropyl cellulose, 0.8-1.5 parts of sodium stearyl fumarate, and 0.08-0.12 parts of sucralose; wherein the average particle size of the microcrystalline cellulose is 15-65 μm.
[0024] In a more preferred embodiment, the orally disintegrating tablet containing brepazole mentioned in the present invention is made of the following components in parts by weight: 2.2 parts of brepazole, 15 parts of microcrystalline cellulose, 69 parts of mannitol, 1 part of sodium starch glycolate, 12 parts of low-substituted hydroxypropyl cellulose, 1 part of sodium stearyl fumarate, and 0.1 part of sucralose; wherein the average particle size of the microcrystalline cellulose is 15 or 65 μm.
[0025] The present invention also provides a method for preparing the orally disintegrating tablet containing brepazole, which comprises the following steps:
[0026] (1) Pretreatment: The active ingredient, borax, is crushed and sieved, and the auxiliary materials are sieved and set aside;
[0027] (2) Preparation of adhesive solution: dispersing sodium carboxymethyl starch in purified water to prepare an adhesive solution;
[0028] (3) granulation: the active ingredients of borax, microcrystalline cellulose, low-substituted hydroxypropyl cellulose and mannitol are uniformly mixed in a fluidized bed, and granulated with the binder solution obtained in step (2), and the obtained wet granules are dried and granulated;
[0029] (4) Mixing and tableting: The granules obtained in step (3) are mixed with sodium stearyl fumarate and a sweetener for tableting. In the present invention, in step (1), the particle size D90 of the active ingredient borax after crushing is 10-50 μm, preferably 20-45 μm. The raw and auxiliary materials are passed through a 60-120 mesh sieve, preferably, the raw and auxiliary materials are passed through an 80 mesh sieve to eliminate the agglomeration caused by static electricity of the micronized raw materials and the agglomeration of the auxiliary materials.
[0030] In the present invention, in step (2), the mass content of sodium carboxymethyl starch in the binder solution is 1-5%, preferably 2%.
[0031] For the present invention, in step (3), when granulating in a fluidized bed, the parameter conditions are set as follows: the air volume during granulation is 80-100HZ; the atomization pressure is 0.05-0.15MPa; when the material temperature is 38-42°C, the binder solution is sprayed into the top spray granulation, the spray speed is 6-10rpm, and the granulation temperature is controlled to be 35-40°C.
[0032] Preferably, in step (3), when granulating in a fluidized bed, the parameter conditions are set as follows: the air volume during granulation is 90HZ, the atomization pressure is 0.1MPa, when the material temperature is 38-42°C, the binder solution is sprayed into the granulator for top spray granulation, the spray speed is 6-10rpm, and the granulation temperature is controlled at 35-40°C.
[0033] Furthermore, the granulation is dried at a temperature of 50-70° C., and then the whole granules are dried through a 40-mesh sieve; preferably, during drying, the drying temperature is 60° C., and the moisture content is controlled to be 1-3%.
[0034] In step (4), during tableting, the hardness is controlled to be 20-50N.
[0035] The fluidized bed granulation mentioned in the present invention is a one-step granulation. The one-step granulation can keep the drug powder in a suspended fluidized state under the action of the airflow from bottom to top. The binder solution will be sprayed into the fluidized chamber from the top or bottom, and the powder will be agglomerated into particles. The mixing, particle forming and drying of the materials are all completed in the same fluidized bed equipment, which reduces the operation links. The active ingredient of this product is brepazole, which is an antipsychotic drug with large toxic and side effects. The one-step fluidized bed granulation can effectively prevent the harm to personnel caused by large dust and cross contamination of materials, and the high efficiency saves production costs.
[0036] In the process of fluidized bed granulation, the present invention controls the average particle size of microcrystalline cellulose and the parameter conditions in the granulation process by selecting specific auxiliary materials and the ratio and dosage between the auxiliary materials, so that the small-scale micronized raw materials in the formula are mixed evenly, and the obtained particles are uniform, have good fluidity, good compression formability, rapid disintegration, fast dissolution rate, and are non-sticky. In addition, the present invention solves the problem of low solubility caused by static electricity, aggregation, and adsorption generated by raw material crushing, and has the advantages of convenience, safety, and effectiveness compared with other preparation methods such as high shear wet granulation.
[0037] Adopt the technical scheme of the present invention, the advantages are as follows:
[0038] The present invention provides an orally disintegrating tablet containing brepazine, wherein sodium carboxymethyl starch is used as a binder, the use of sodium carboxymethyl starch is expanded, mannitol and microcrystalline cellulose are used as fillers, and the ratio and dosage between various auxiliary materials are controlled, thereby solving the adverse effects caused by the surface properties of small-scale micronized raw materials in the preparation process of the orally disintegrating tablet, and the one-step granulation of the fluidized bed is used to solve the safety problems caused by more and uneven fine powder particles and poor taste in the ordinary wet granulation process and the active substance being the antipsychotic drug of brepazine. In addition, the particles prepared by the present invention have good uniform fluidity, solve the problems of sticking and punching in the tableting process, poor compressibility or overtime of disintegration time limit of large particles, significantly improve disintegration time and dissolution rate, ensure bioavailability, have the advantages of simple preparation method, high safety, rapid disintegration of the obtained sample, rapid dissolution, good compression formability, good uniformity, high stability, etc., and are suitable for large-scale industrial production. BRIEF DESCRIPTION OF THE DRAWINGS
[0039] Figure 1 It is the dissolution curve of the orally disintegrating tablet prepared in the examples and comparative examples. DETAILED DESCRIPTION
[0040] The present invention can be better understood according to the following examples. However, it is easy for those skilled in the art to understand that the contents described in the examples are only used to illustrate the present invention, and should not and will not limit the present invention described in detail in the claims.
[0041] Example
[0042] An orally disintegrating tablet containing brepazole is prepared from the following components in parts by weight, as shown in Table 1.
[0043] Table 1 Raw materials and auxiliary materials of orally disintegrating tablets of breprazol
[0044] Raw materials Example 1 Example 2 Brepiraazole 2.2 servings 2.2 servings Mannitol 69% 69 copies Microcrystalline Cellulose 15 servings 15 servings Low substituted hydroxypropyl cellulose 12 servings 12 servings Sodium starch glycolate 1 serving 1 serving Sodium Stearoyl Fumarate 1 serving 1 serving Sucralose 0.1 part 0.1 part
[0045] The method for preparing the orally disintegrating tablet in Example 1 comprises the following steps:
[0046] (1) Pretreatment: The active ingredient brepazole is crushed to a particle size D90 of 20-45 μm; the crushed brepazole, auxiliary materials mannitol, microcrystalline cellulose (average particle size of 15 μm) and low-substituted hydroxypropyl cellulose are sieved through an 80-mesh sieve for later use;
[0047] (2) Preparation of adhesive solution: sodium carboxymethyl starch was dispersed in 50 parts of purified water to prepare an adhesive solution having a sodium carboxymethyl starch content of 2%;
[0048] (3) Granulation: the active components of the processed ingredients of borax, microcrystalline cellulose, low-substituted hydroxypropyl cellulose and mannitol in step (1) are placed in a fluidized bed, mixed for 5 min at an air volume of 80 Hz, and the obtained mixture is granulated with the binder solution obtained in step (2) in a fluidized bed, and the parameter conditions are set as follows: the air volume during granulation is 90 Hz; the atomization pressure is 0.1 MPa; when the material temperature is 38-42°C, the binder solution is sprayed into the granulation by top spraying, the spraying speed is 6-10 rpm, and the granulation temperature is controlled at 35-40°C; the obtained wet granules are dried at a drying temperature of 60°C and the moisture content is controlled to be 1-3%; the granules are sieved through a 40-mesh sieve after drying;
[0049] (4) Mixing and tableting: Sucralose, sodium stearyl fumarate and the granules obtained in step (3) are mixed in a hopper mixer at a speed of 20 rpm for 10 minutes, and then tableted to control the hardness to 20-50N.
[0050] The preparation method of the orodisintegrating tablet in Example 2 is the same as that in Example 1, except that the average particle size of the microcrystalline cellulose is adjusted from 15 μm to 65 μm.
[0051] Comparative Example
[0052] An orally disintegrating tablet containing brepazole is prepared from the following components in parts by weight, as shown in Table 2.
[0053] Table 2 Raw materials and auxiliary materials of orally disintegrating tablets of breprazol
[0054] Raw materials Comparative Example 1 Comparative Example 2 Comparative Example 3 Comparative Example 4 Comparative Example 5 Comparative Example 6 Brepiraazole 2.2 servings 2.2 servings 2.2 servings 2.2 servings 2.2 servings 2.2 servings Mannitol 69 copies 69 copies 69 copies 69 copies 68 servings 69 copies Microcrystalline Cellulose 15 servings 15 servings 15 servings 15 servings 15 servings 15 servings Low substituted hydroxypropyl cellulose 12 servings 12 servings 12 servings 12 servings 12 servings 12 servings Sodium starch glycolate / / / / 3 servings 1 serving Hydroxypropylcellulose 1 serving / / / / / Hydroxypropyl methylcellulose / 1 serving / / / / Povidone K30 / / 1 serving / / / Polyvinyl alcohol / / / 1 serving / / Sodium Stearoyl Fumarate 1 serving 1 serving 1 serving 1 serving 1 serving 1 serving Sucralose 0.1 part 0.1 part 0.1 part 0.1 part 0.1 part 0.1 part
[0055] The preparation method of the orally disintegrating tablet in the comparative example is referred to Example 1. Taking Comparative Example 1 as an example, sodium carboxymethyl starch is replaced with hydroxypropyl cellulose, and the preparation method thereof comprises the following steps:
[0056] (1) Pretreatment: The active ingredient brepazole is crushed to a particle size D90 of 20-45 μm; the crushed brepazole, auxiliary materials mannitol, microcrystalline cellulose (average particle size of 15 μm) and low-substituted hydroxypropyl cellulose are sieved through an 80-mesh sieve for later use;
[0057] (2) Preparation of adhesive solution: Hydroxypropyl cellulose was dissolved in 50 parts of purified water to prepare an adhesive solution having a sodium carboxymethyl starch content of 2%;
[0058] (3) Granulation: the active components of the processed ingredients of borax, microcrystalline cellulose, low-substituted hydroxypropyl cellulose and mannitol in step (1) are placed in a fluidized bed, mixed for 5 min at an air volume of 80 Hz, and the obtained mixture is granulated with the binder solution obtained in step (2) in a fluidized bed, and the parameter conditions are set as follows: the air volume during granulation is 90 Hz; the atomization pressure is 0.1 MPa; when the material temperature is 38-42°C, the binder solution is sprayed into the granulation by top spraying, the spraying speed is 6-10 rpm, and the granulation temperature is controlled at 35-40°C; the obtained wet granules are dried at a drying temperature of 60°C and the moisture content is controlled to be 1-3%; the granules are sieved through a 40-mesh sieve after drying;
[0059] (4) Mixing and tableting: Sucralose, sodium stearyl fumarate and the granules obtained in step (3) are mixed in a hopper mixer at a speed of 20 rpm for 10 minutes, and then tableted to control the hardness to 20-50N.
[0060] The preparation method of Comparative Examples 2-4 refers to that of Example 1, except that sodium starch glycolate is replaced with hydroxypropyl methylcellulose, povidone K30 and polyvinyl alcohol in sequence.
[0061] The preparation method in Comparative Example 5 is the same as that in Example 1, except that the amount of sodium carboxymethyl starch is replaced from 1 part to 3 parts.
[0062] The preparation method in Comparative Example 6 is the same as that in Example 1, except that the average particle size of the microcrystalline cellulose is adjusted from 15 μm to 100 μm.
[0063] Comparative Example 7
[0064] The breprazol orally disintegrating tablets were prepared according to the formulation and preparation method in Example 1 disclosed in patent CN106580902A.
[0065] Comparative Example 8
[0066] The breprazol orally disintegrating tablets were prepared according to the formulation and preparation method disclosed in Example 2 disclosed in patent CN106580902A.
[0067] Comparative Example 9
[0068] The breprazol orally disintegrating tablets were prepared according to the formulation and preparation method disclosed in Example 4b of patent application CN 115998694A.
[0069] Performance data:
[0070] Dissolution curve determination: paddle method, dissolution medium: acetic acid-sodium acetate buffer (pH 4.3), dissolution medium dosage: 900 ml, rotation speed: 50 rpm, sampling time points: 5, 10, 15, 20, 30, 45, 60 min, take 10 ml of solution (add the same volume of solvent at the same time), filter through water membrane, take appropriate amount of filtrate and dilute it as the test solution.
[0071] Reference solution: Take an appropriate amount of brepazine reference substance, weigh accurately, add dissolution medium to dissolve and quantitatively dilute to make a solution containing approximately 2.22 μg of brepazine per 1 ml.
[0072] Determination method: High performance liquid chromatography
[0073] The smoothness of the tableting process, tablet quality, dissolution comparison data of the breprazol orally disintegrating tablets prepared in the examples and comparative examples and the dissolution curves in acetic acid-sodium acetate buffer (pH 4.3) were investigated. The results are shown in Tables 3 and 4.
[0074] Table 3 Comparative data of smoothness of tablet compression process, tablet quality and dissolution of breprazol orally disintegrating tablets prepared in Examples and Comparative Examples
[0075]
[0076] As shown in Table 3, the orally disintegrating tablets prepared by different adhesives are compared. The orally disintegrating tablets obtained by fluidized bed granulation (Examples 1-2) using sodium carboxymethyl starch as an adhesive are compared with the orally disintegrating tablets obtained by fluidized bed granulation using other adhesives such as hydroxypropyl cellulose, hypromellose, povidone K30, and polyvinyl alcohol (Comparative Examples 1-4). The disintegration time limit of the sample of sodium carboxymethyl starch as an adhesive meets the requirements and disintegrates rapidly, while the disintegration time limit of the other adhesive groups is greater than 60s, exceeding the standard of 1min. In addition, samples prepared by different amounts of adhesives and other auxiliary materials do not have the same degree of sticking or a large main pressure phenomenon during tableting.
[0077] In Examples 1 and 2 provided by the present invention, sodium carboxymethyl starch is selected as a binder and the particle size of microcrystalline fibers is controlled between 15 and 65 μm. The prepared tablets have no signs of sticking, are smooth on the tablet surface, have good tablet core brittleness index, and are rapidly dissolved. The other comparative examples have the disadvantages of sticking, unqualified content uniformity, timed disintegration, and poor taste to varying degrees. Among them, when the dosage of sodium carboxymethyl starch is 3 parts (Comparative Example 5), the disintegration time of the obtained sample does not meet the quality standard requirement that the orally disintegrating tablet shall not exceed 1 minute, and the main pressure during tableting is relatively large, which is not conducive to the smooth tableting; the average particle size of microcrystalline cellulose is 100 μm, which is not within the scope of this application (Comparative Example 6). Although the tablets prepared do not stick to the punches, the disintegration and dissolution are slow, and the mouthfeel is slightly gritty; the disintegration time and dissolution of the samples prepared by high shear granulation are both slow, and the mouthfeel is gritty; the disintegration time of the samples prepared by the powder direct compression process (Comparative Example 9) meets the standard, but the dissolution is relatively slow. At the same time, a large amount of glidants and lubricants are used in the formula to solve the sticking problem, resulting in a decrease in dissolution rate and poor stability.
[0078] Table 4 Dissolution curve results of breprazol oral tablets prepared in Examples and Comparative Examples
[0079]
[0080] As shown in Table 4, the particles prepared by using sodium carboxymethyl starch as a binder for fluidized bed granulation (Examples 1-2) are loose and uniform compared to others, and the dissolution rate is very fast and uniform, and the dissolution rate is faster than other granulation methods. In addition, in Examples 1 and 2 provided by the present invention, sodium carboxymethyl starch is used as a binder and the microcrystalline fiber particle size is controlled between 15-65 μm, dissolution is faster, and the dissolution endpoint is more completely dissolved out, and a high shear granulation method is used. Due to the high granulation intensity, a part of hard particles will appear, causing dissolution to be slow; direct powder pressing granulation causes dissolution to be slightly slow due to the use of a large amount of retention aids and lubricants.
[0081] It can be seen from Examples 1-2 and Comparative Example 6 that when microcrystalline cellulose is used as a filler, its particle size needs to be strictly controlled. Comparative Example 6 shows that when the particle size of microcrystalline cellulose is larger, the tablet surface is dull and the disintegration time is exceeded. In addition, the taste is gritty compared to the sample prepared from microcrystalline cellulose with a smaller particle size, the bitterness masking effect is relatively poor, and the dissolution is relatively incomplete. Therefore, when the present invention selects microcrystalline cellulose as a filler, the average particle size is controlled to be 10-80 μm, preferably 15-65 μm.
[0082] The samples prepared in the embodiment and the comparative example were placed in an environment of 40±2°C and RH75%±5% for 6 months. The total impurity content of the orally disintegrating tablets of brepirazole at 0 day and 6 months was detected by high performance liquid chromatography. The experimental results are shown in Table 5:
[0083] Table 5 Results of related substances of breprazol oral tablets prepared in Examples and Comparative Examples
[0084]
[0085]
[0086] The above results show that the orally disintegrating tablets prepared in Examples 1 and 2 of the present invention have no significant changes in disintegration time and content of related substances when accelerated for six months, and have good stability. Among them, the tablets prepared in Comparative Examples 1-9 have significantly increased disintegration time and content of related substances, and have poor stability.
[0087] The above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, a person skilled in the art should understand that it is still possible to modify the technical solutions described in the aforementioned embodiments, or to perform equivalent replacements on some of the technical features therein. However, these modifications or replacements do not cause the essence of the corresponding technical solutions to deviate from the scope of the technical solutions of the embodiments of the present invention.
Claims
1. An orally disintegrating tablet containing brepazole, It is characterized in that The orally disintegrating tablet is prepared from the following components in parts by weight: 0.5-5 parts of active ingredient boripiprazole, 5-25 parts of microcrystalline cellulose, 60-80 parts of mannitol, 0.5-2 parts of sodium carboxymethyl starch, 6-18 parts of low-substituted hydroxypropyl cellulose, 0.5-2 parts of sodium stearyl fumarate, and 0.05-0.15 parts of a sweetener; wherein the average particle size of the microcrystalline cellulose is 10-80 μm; and the sweetener is one or more of strawberry flavor, mint flavor, sucrose, sucralose or aspartame.
2. The orally disintegrating tablet containing brepazole according to claim 1, It is characterized in that In the preparation process of the orally disintegrating tablet, the active ingredients of borax, microcrystalline cellulose and mannitol are firstly mixed evenly, and then fluidized bed granulated with a binder solution prepared by dispersing sodium carboxymethyl starch in purified water. The obtained wet granules are dried and granulated; and then mixed with sodium stearyl fumarate and a sweetener for tableting.
3. The orally disintegrating tablet containing brepazole according to claim 2, It is characterized in that The orally disintegrating tablet is prepared from the following components in parts by weight: 2-3 parts of brepirazole, 10-20 parts of microcrystalline cellulose, 65-75 parts of mannitol, 0.8-1.5 parts of sodium starch glycolate, 10-14 parts of low-substituted hydroxypropyl cellulose, 0.8-1.5 parts of sodium stearyl fumarate, and 0.08-0.12 parts of sucralose; wherein the average particle size of the microcrystalline cellulose is 15-65 μm.
4. The orally disintegrating tablet containing brepizole according to claim 3, It is characterized in that The orally disintegrating tablet is prepared from the following components in parts by weight: 2.2 parts of breprazol, 15 parts of microcrystalline cellulose, 69 parts of mannitol, 1 part of sodium carboxymethyl starch, 12 parts of low-substituted hydroxypropyl cellulose, 1 part of sodium stearyl fumarate, and 0.1 part of sucralose; wherein the average particle size of the microcrystalline cellulose is 15 or 65 μm.
5. The method for preparing the orally disintegrating tablet containing brepazole according to claim 1, It is characterized in that It includes the following steps: (1) Pretreatment: The active ingredient, borax, is crushed and sieved, and the auxiliary materials are sieved and set aside; (2) Preparation of adhesive solution: dispersing sodium carboxymethyl starch in purified water to prepare an adhesive solution; (3) granulation: the active ingredients of borax, microcrystalline cellulose, low-substituted hydroxypropyl cellulose and mannitol are uniformly mixed in a fluidized bed, and granulated with the binder solution obtained in step (2), and the obtained wet granules are dried and granulated; (4) Mixing and tableting: The granules obtained in step (3) are mixed with sodium stearyl fumarate and a sweetener and tableted.
6. The method for preparing the orally disintegrating tablet containing brepazole according to claim 5, It is characterized in that In step (1), the particle size D90 of the active ingredient Beriprazole after crushing is 10-50 μm, preferably 20-45 μm; the crushed active ingredient and excipients are sieved through a 60-120 mesh sieve, preferably 80 mesh.
7. The method for preparing the orally disintegrating tablet containing brepazole according to claim 5, It is characterized in that In step (2), the mass content of sodium carboxymethyl starch in the adhesive solution is 1-5%, preferably 2%.
8. The method for preparing the orally disintegrating tablet containing brepazole according to claim 5, It is characterized in that In step (3), when granulating in a fluidized bed, the parameter conditions are set as follows: the air volume during granulation is 80-100HZ, preferably 90HZ; the atomization pressure is 0.05-0.15MPa, preferably 0.1MPa; when the material temperature is 38-42°C, the binder solution is sprayed into the top spray granulation, the spray speed is 6-10rpm, and the granulation temperature is controlled at 35-40°C.
9. The method for preparing the orally disintegrating tablet containing breprazol according to claim 8, It is characterized in that In step (3), the drying temperature is 50-70° C., and the whole granules are dried through a 40-mesh sieve; preferably, during drying, the drying temperature is 60° C., and the moisture content is controlled to be 1-3%.
10. The method for preparing the orally disintegrating tablet containing brepazole according to claim 5, It is characterized in that The orally disintegrating tablet is prepared from the following components in parts by weight: 2-3 parts of brepirazole, 10-20 parts of microcrystalline cellulose, 65-75 parts of mannitol, 0.8-1.5 parts of sodium starch glycolate, 10-14 parts of low-substituted hydroxypropyl cellulose, 0.8-1.5 parts of sodium stearyl fumarate, and 0.08-0.12 parts of sucralose; wherein the average particle size of the microcrystalline cellulose is 15-65 μm.
Citation Information
Cited By
Brexpiprazole tablet and preparation method thereof
CN119656120A
Baclofen tablet and preparation method thereof
CN119679738A
A baclofen tablet and its preparation method
CN119679738B
